CALCIUM ACETATE

The United States Food and Drug Administration (FDA) granted initial approval to calcium acetate on 15 January 2002.

Calcium acetate is primarily used for managing elevated levels of phosphate in the blood, a condition known as hyperphosphatemia. It is prescribed for individuals with chronic kidney disease (CKD) and end-stage renal disease (ESRD), particularly those undergoing dialysis. It helps prevent phosphate absorption into the bloodstream.

Calcium acetate is typically administered orally, meaning it is taken by mouth in the form of tablets or capsules. The medication is designed to be swallowed with water and should not be chewed or crushed unless specifically instructed by a healthcare provider. The oral route is the most common and effective way to use this medication for managing hyperphosphatemia in individuals with chronic kidney disease and end-stage renal disease.

Common side effects of Calcium acetate include upset stomach, constipation, abdominal pain, loss of appetite, itching, and the potential for hypocalcemia (low blood calcium levels). These effects are often manageable and may improve with time. However, more serious side effects can occur, such as hypercalcemia (high blood calcium levels), which can lead to symptoms like nausea, vomiting, confusion, and muscle weakness. Prolonged use may result in the deposition of calcium in soft tissues or aluminum toxicity, particularly in formulations containing aluminum.

Calcium acetate can increase blood calcium levels, potentially leading to hypercalcemia. Be cautious if using its formulations containing aluminum, as prolonged use can contribute to aluminum toxicity. Prolonged use of this medication may lead to calcium deposition in soft tissues, including blood vessels and heart valves. It can lower blood calcium levels, leading to hypocalcemia. Symptoms of hypocalcemia include muscle cramps, numbness, and tingling. Prolonged use of this medication can also impact calcium-phosphate balance and bone metabolism.

Patients with a history of hypercalcemia or conditions that increase the risk of elevated blood calcium levels should consult a doctor before starting Calcium acetate. Consult your healthcare provider to determine the most suitable formulation. Close monitoring and appropriate calcium and phosphate control are recommended in long term patients. Regular monitoring of blood calcium levels and prompt intervention are essential to maintain proper calcium balance and prevent complications.follow recommended calcium and vitamin D intake guidelines by the doctor to prevent bone-related complications.

Inform your healthcare provider of your complete medical history, allergies, and any current medications or supplements to ensure safe usage. Regular monitoring of blood phosphate levels is important to assess how effectively calcium acetate manages hyperphosphatemia. Follow dietary recommendations provided by your healthcare provider to complement the medication's effects. Watch for symptoms of hypercalcaemia, such as nausea, vomiting, and confusion, as well as symptoms of hypocalcaemia. If you experience any adverse effects, inform your healthcare provider, who may adjust the dosage or recommend alternative treatments. Pregnant and breastfeeding patients should seek guidance from a healthcare provider before using this medication. If you have underlying conditions such as liver or lung issues, discuss them with your healthcare provider before starting treatment. Always consult your healthcare provider for personalised advice and guidance on the safe and effective use of this medication in your specific circumstances.

RenaCare NephroMed GmbH, Electronic Medicines Compendium (EMC), [Revised on Feb 2012] [Accessed on 22 August 2023], https://www.medicines.org.uk/emc/files/pil.4646.pdf Genzyme Ireland Ltd, US Food and Drug Administration, [Revised on: 04/2020 ] [Accessed on 23rd August 2023] , https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022127s019,022318s021lbl.pdf J. Goddard, A.N. Turner, Kidney and Urinary Tract Disease, Davidson’s Principles and Practice of Medicine, 22nd Edition, 2014, 461-523.